Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
Álvaro Díaz-GonzálezManuel Hernández GuerraIndhira Pérez-MedranoVíctor SapenaMar RiveiroAna Barreira DíazElena GómezRosa Mª MorillasMaría Del BarrioLaia EscudéBeatriz MateosDiana HortaJudith GómezIsabel CondeCarlos FerreIsmael El HajraAna ArencibíaJavier M Zamora-OlayaAhinoa Fernández MorenoMagdalena Salcedo PlazaEsther MolinaAnna SoriaPamela EstévezCarmen LópezMontserrat García-RetortilloJavier CrespoMaría Carlota Londoñonull nullPublished in: Hepatology (Baltimore, Md.) (2023)
In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.